BC066135 Inhibitors
BC066135, a protein intricately involved in cellular processes, plays a crucial role in maintaining genomic stability through its participation in DNA repair mechanisms and gene regulation. Functionally, BC066135 is intricately linked to the cellular response to DNA damage, contributing to the fidelity of genetic information transfer during cell division. The general mechanisms of inhibition for BC066135 inhibitors involve targeted disruptions of specific molecular interactions or signaling pathways. Direct inhibitors, such as Veliparib and Rucaparib, directly target BC066135 by inhibiting PARP enzymatic activity, crucial for DNA repair. In contrast, indirect inhibitors like AZD7762 and VE-822 disrupt the CHK1/2 and ATR-mediated DNA damage response pathways, respectively, indirectly impacting BC066135-associated cellular processes. These inhibitors illustrate the interconnected nature of DNA damage response pathways and BC066135 function.
Additionally, epigenetic modulators like BIX 01294 and GSK-J4 directly influence BC066135 by modulating histone methylation and demethylation, emphasizing the role of epigenetic modifications in BC066135-mediated gene regulation. The intricate interplay between BC066135 and chromatin modifications highlights the diverse mechanisms through which inhibitors can influence its cellular functions. Furthermore, inhibitors such as SP600125 and NU7441 disrupt the JNK and DNA-PK-mediated DNA damage response pathways, respectively, providing insights into the indirect modulation of BC066135 through interconnected signaling cascades. The multifaceted nature of BC066135's involvement in cellular processes underscores the potential for targeted interventions in various pathways, offering avenues for further exploration in understanding and manipulating genomic stability.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $178.00 $270.00 $712.00 | 3 | |
Veliparib, a PARP inhibitor, directly targets BC066135 by inhibiting PARP enzymatic activity. BC066135 is involved in DNA repair processes, and Veliparib's inhibition of PARP interferes with DNA repair, directly affecting BC066135-mediated repair mechanisms. The disruption of this enzymatic activity directly influences BC066135, impacting its role in maintaining genomic integrity. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $36.00 $110.00 $400.00 | ||
BIX01294 hydrochloride, a G9a histone methyltransferase inhibitor, directly influences BC066135 by modulating histone methylation. BC066135 associates with chromatin, and BIX 01294's action on G9a alters histone methylation patterns, directly affecting BC066135-mediated gene regulation. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762, a CHK1 inhibitor, indirectly influences BC066135 by disrupting the CHK1-mediated DNA damage response. BC066135 is involved in DNA repair pathways, and AZD7762's action on CHK1 interferes with downstream signaling events, indirectly impacting BC066135-associated cellular processes. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
C646, a histone acetyltransferase inhibitor, directly influences BC066135 by modulating histone acetylation. BC066135 associates with chromatin, and C646's action on histone acetyltransferases alters histone acetylation patterns, directly affecting BC066135-mediated gene regulation. | ||||||
LY2606368 | 1234015-52-1 | sc-507521 sc-507521A sc-507521B sc-507521C sc-507521D sc-507521E | 5 mg 10 mg 25 mg 100 mg 1 g 10 g | $176.00 $300.00 $500.00 $1900.00 $8000.00 $25000.00 | ||
LY2606368, a CHK1/2 inhibitor, indirectly influences BC066135 by disrupting the CHK1/2-mediated DNA damage response. BC066135 is involved in DNA repair pathways, and LY2606368's action on CHK1/2 interferes with downstream signaling events, indirectly impacting BC066135-associated cellular processes. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4, a JMJD3 histone demethylase inhibitor, directly influences BC066135 by modulating histone demethylation. BC066135 associates with chromatin, and GSK-J4's action on JMJD3 alters histone demethylation patterns, directly affecting BC066135-mediated gene regulation. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
Rucaparib, a PARP inhibitor, directly targets BC066135 by inhibiting PARP enzymatic activity. BC066135 is involved in DNA repair processes, and Rucaparib's inhibition of PARP interferes with DNA repair, directly affecting BC066135-mediated repair mechanisms. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly influences BC066135 by disrupting the JNK signaling pathway. BC066135 interacts with components of the JNK pathway, and SP600125's action on JNK interferes with this interaction, indirectly impacting BC066135-associated cellular processes and downstream signaling events. | ||||||
UNC0638 | 1255580-76-7 | sc-397012 | 10 mg | $315.00 | ||
UNC0638, a G9a/GLP histone methyltransferase inhibitor, directly influences BC066135 by modulating histone methylation. BC066135 associates with chromatin, and UNC0638's action on G9a/GLP alters histone methylation patterns, directly affecting BC066135-mediated gene regulation. | ||||||
EPZ005687 | 1396772-26-1 | sc-497734 | 2.5 mg | $380.00 | ||
EPZ005687, a DOT1L histone methyltransferase inhibitor, directly influences BC066135 by modulating histone methylation. BC066135 associates with chromatin, and EPZ005687's action on DOT1L alters histone methylation patterns, directly affecting BC066135-mediated gene regulation. | ||||||